Momenta biosimilar matches Humira in Phase III trial

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) announced biosimilar candidate M923 showed equivalence to reference product Humira adalimumab,

Read the full 156 word article

User Sign In